Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trialPepijn Eijsvogel, Jean‐Cosme Dodart, Marieke L. de Kam et al.|Nature Medicine|2024Cited by 38
Preclinical characterization of an active immunotherapy targeting calcitonin gene-related peptideJustin D. Boyd, Jean‐Cosme Dodart, Shixia Wang et al.|Communications Medicine|2025Cited by 2